Last reviewed · How we verify
NCT02277483: korLAIS
Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma
Phase 4 trial testing LAIS® in Allergic Conditions in 45 participants. Status unknown.
1 July 2016
Quick facts
| Lead sponsor | Ajou University School of Medicine |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 1 October 2014 |
| Primary completion | 1 July 2016 |
| Estimated completion | 1 December 2016 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- LAIS® — full drug profile →
Conditions studied
- Allergic Conditions — all drugs for Allergic Conditions →
Sponsor
Ajou University School of Medicine
Who can join
60 and older, any sex, with Allergic Conditions. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Total combined score (TCS)
Time frame: up to 48 weeks
TCS = rhinoconjunctivitis total symptom score (RTSS) and the total rescue medication score (RTMS)
Sponsor's own description
Evaluation of the efficacy and safety of SLIT with LAIS® Mites Sublingual tablets compared to standard drug treatment in patients aged over 60 years suffering from house dust mite (HDM) induced allergic rhino-conjunctivitis with/without asthma.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Sublingual immunotherapy for asthma.
Normansell R, Kew KM, Bridgman AL. · · 2015 · cited 40× · PMID 26315994 · DOI 10.1002/14651858.cd011293.pub2 -
Sublingual immunotherapy for asthma.
Fortescue R, Kew KM, Leung MST. · · 2020 · cited 23× · PMID 32926419 · DOI 10.1002/14651858.cd011293.pub3
Verify or expand the search:
- PubMed search for NCT02277483
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Ajou University School of Medicine trials
Trials by the same sponsor.
- NCT07101380 — Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients · NA · recruiting
- NCT07395752 — Youth Suicide and Self-Harm Intervention: Clinical and Biological Outcomes Study · NA · recruiting
- NCT06964217 — Immediate Fracture Risk After Antihypertensive Drug Initiation · not yet recruiting
- NCT05751603 — Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex · NA · not yet recruiting
- NCT07479160 — Heart to Heart Web-based Communication Program for Heart Failure · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02277483 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ajou University School of Medicine
- Last refreshed: 21 June 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02277483.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing